ArticleCell reports2016
PYY-Dependent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass Surgery.
Article in Cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05616273 (Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes), which is not on this map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Effect of bariatric surgery on glycemic and metabolic outcomes in people with obesity and type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-evidence of 39 studies.Frontiers in nutrition · 2025Pooled it
- High-throughput mediation analysis of human proteome and metabolome identifies mediators of post-bariatric surgical diabetes control.Nature communications · 2021Trial
- Future GLP-1 receptor co-agonists and their cardiac effects.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Duodenal myoelectrical hyperactivity drives diabetic remission in rat models of type 2 diabetes.Diabetologia · 2026Article
- The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.The Journal of clinical investigation · 2026Review
- The role of PYY in improving insulin resistance.Frontiers in endocrinology · 2026Review
- Gastrectomy promoted diabetes remission involves the molecular clock and epigenetic mechanisms in a rat model of lean type 2 diabetes.Scientific reports · 2025Article
- Peptide YY in Type 2 Diabetes: A Complementary Gut Hormone with Therapeutic Potential Beyond GLP-1.Nutrients · 2025Review
- The role of gut-islet axis in pancreatic islet function and glucose homeostasis.Diabetes, obesity & metabolism · 2025Review
- Transcriptome atlases of rat brain regions and their adaptation to diabetes resolution following gastrectomy in the Goto-Kakizaki rat.Molecular brain · 2025Article
- Intestinal IL-22RA1 signaling regulates intrinsic and systemic lipid and glucose metabolism to alleviate obesity-associated disorders.Nature communications · 2024Article
- Research progress on the mechanism of TCM regulating intestinal microbiota in the treatment of DM mellitus.Frontiers in endocrinology · 2024Review
- Retinal and metabolic changes in a high-fat diet (HFD)+STZ model of Type II diabetes.Molecular vision · 2024Article
- Periodontal bacteria influence systemic diseases through the gut microbiota.Frontiers in cellular and infection microbiology · 2024Review
- Dorothy Hodgkin lecture 2023: The enteroendocrine system-Sensors in your guts.Diabetic medicine : a journal of the British Diabetic Association · 2023Review
- Incretin hormones and type 2 diabetes.Diabetologia · 2023Review
- Mechanisms of bariatric surgery for weight loss and diabetes remission.Journal of diabetes · 2023Review
- The postprandial secretion of peptide YYClinical endocrinology · 2023Article
- Beta-cell mass adaptation to ileum nutrient flow. An experimental model.Histology and histopathology · 2023Article
- Effects of bariatric surgery and dietary intervention on insulin resistance and appetite hormones over a 3 year period.Scientific reports · 2023Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
Roux-en-Y gastric bypass (RYGB) is a weight-reduction procedure resulting in rapid resolution of type 2 diabetes (T2D). The role of pancreatic islet function in this restoration of normoglycemia has not been fully elucidated. Using the diabetic Goto-Kakizaki (GK) rat model, we demonstrate that RYGB restores normal glucose regulation of glucagon and insulin secretion and normalizes islet morphology. Culture of isolated islets with serum from RYGB animals mimicked these effects, implicating a humoral factor. These latter effects were reversed following neutralization of the gut hormone peptide tyrosine tyrosine (PYY) but persisted in the presence of a glucagon-like peptide-1 (GLP-1) receptor antagonist. The effects of RYGB on secretion were replicated by chronic exposure of diabetic rat islets to PYY in vitro. These findings indicate that the mechanism underlying T2D remission may be mediated by PYY and suggest that drugs promoting PYY release or action may restore pancreatic islet function in T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.